Tevogen Bio (NASDAQ:TVGN) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Tevogen Bio (NASDAQ:TVGN) to a strong sell rating in a research note released on Saturday.

Several other brokerages also recently commented on TVGN. Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital cut shares of Tevogen Bio from a “buy” rating to a “hold” rating in a report on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $100.00.

Tevogen Bio Price Performance

NASDAQ:TVGN opened at $5.55 on Friday. The business’s 50-day simple moving average is $12.44 and its 200-day simple moving average is $22.68. Tevogen Bio has a fifty-two week low of $4.89 and a fifty-two week high of $75.50. The stock has a market capitalization of $22.48 million, a PE ratio of -0.58 and a beta of -0.76.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TVGN. Bridgeway Capital Management LLC raised its position in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after buying an additional 33,000 shares during the last quarter. Deutsche Bank AG boosted its position in Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after acquiring an additional 130,738 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after acquiring an additional 152,572 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.